Genolution

Genolution EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Genolution (225220.KQ) as of Oct 22, 2026 is -9.21 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -8.91 % — a change of 3.38% (lower).

EBIT/Assets

-9.21 %

YoY

3.38%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Genolution is 2025 -9.21 % . Operating Income to Assets Ratio (EBIT/Assets) of Genolution was 2024 -8.91 % . It decreases by 3.38% lower compared to the previous year.

The Genolution EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
1.65 KRW
Jan 1, 2019
1.10 KRW
Jan 1, 2020
64.51 KRW
Jan 1, 2021
45.90 KRW
Jan 1, 2022
13.10 KRW
Jan 1, 2023
-7.17 KRW
Jan 1, 2024
-8.91 KRW
Jan 1, 2025
-9.21 KRW
The Genolution EBIT/Assets history
YEAREBIT/AssetsYoY
-9.21 %+3.38%
-8.91 %+24.27%
-7.17 %-154.73%
13.10 %-71.45%
45.90 %-28.85%
64.51 %+5,752.01%
1.10 %-33.02%
1.65 %-87.67%
13.35 %+584.15%
1.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Operating Income to Assets Ratio (EBIT/Assets) of Genolution is -9.21 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Genolution changed from -8.91 % to -9.21 %, representing a 3.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Genolution since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genolution

All Key Metrics — Genolution